Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Functional phenotyping reveals differential cellular responses to umbralisib treatment in responders and nonresponders; predicts treatment response of individual patients with CLL; and suggests alternative treatment options for the nonresponders.
Authors
- Jennifer R. Brown (ORCID: https://orcid.org/0000-0003-2040-4961)
- Tero A. Aittokallio (ORCID: https://orcid.org/0000-0002-0886-9769)
- Haifeng Xu (ORCID: https://orcid.org/0000-0003-0165-6709)
- Yanping Yin (ORCID: https://orcid.org/0000-0003-0481-5955)
- Sigrid S. Skånland (ORCID: https://orcid.org/0000-0003-1630-356X)
- Liye He (ORCID: https://orcid.org/0000-0002-6632-2112)
- Anthony R. Mato (ORCID: https://orcid.org/0000-0001-8724-1875)
Institutions
- Oslo University Hospital (NO)
- Memorial Sloan Kettering Cancer Center (US)
- University of Helsinki (FI)
- Harvard University (US)
- University of Oslo (NO)
- Kettering University (US)
- Dana-Farber Cancer Institute (US)
- Cancer Registry of Norway (NO)
- Institute for Molecular Medicine Finland (FI)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2911
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25